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Nanotechnology is increasingly finding use in the management of cancer. Nanoscale devices have impacted cancer biology at three
levels: early detection using, for example, nanocantilevers or nanoparticles; tumour imaging using radiocontrast nanoparticles or
quantum dots; and drug delivery using nanovectors and hybrid nanoparticles. This review addresses some of the major milestones in
the integration of nanotechnology and cancer biology, and the future of nanoscale approaches for cancer management.
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‘The principles of physics, as far as I can see, do not speak against
the possibility of manoeuvreing things atom by atom’ – Feynman
(1959). Since Feynman’s talk at the annual meeting of the
American Physical Society in December 1959, we have made
significant progress in enabling nanotechnology for revolutionis-
ing medicine. In cancer biology this has translated into major
advances in primarily three areas: early detection, tumour imaging
and drug delivery. In this article, we highlight some of the key
nanotechnologies in each of these three areas, with a brief
discussion of the challenges and advances for each approach.
DRIVERS FOR DEVELOPMENTS IN
NANOTECHNOLOGY
The drivers for advances in nanotechnology have been the
development of tools that enable us to manipulate at an atomic
scale, and materials and chemistry that allow the constructions
of novel structures. Although it is not the focus of this review to
address these tools in details, it is important to realise potentials of
these analytical and fabrication tools, which if integrated with
fundamental biology can provide essential breakthroughs in the
fight against cancer.
It was originally the electron microscope, with scanning or
transmission capabilities, which was used to image at the
nanoscale range, but it was limited by the steps involved in the
preparation of the object to be imaged. More recently, scanning
probe devices have been enormously successful in biological
manipulations at the single molecule level (Engel et al, 1999). An
interesting adaptation of the scanning probe devices has been
the Scanning Tunneling Microscope, which uses ‘tunnelling’ or the
flow of electrons from a probe tip to a charged surface and vice
versa to generate the contours of a surface (Horber and Miles,
2003), or to move a structure atom by atom. Another modification
is the use of the cantilever technology to detect tumour markers
(Wu et al, 2001). Furthermore, the scanning probe device has also
been integrated with wet lithography techniques in an approach
called the dip pen nanolithography, to print designer nanoscale
structures in three dimensions (Piner et al, 1999).
NANOTECHNOLOGY AND BIOSENSORS
The successful outcome of cancer chemotherapy often depends on
the early detection of the cancer lesion. However, in most cases the
transformation remains undetected until clinical manifestations,
arising primarily from the absence of highly sensitive techniques
that can detect low levels of markers. Furthermore, clinically
relevant markers, such as prostate serum antigen (PSA), have a
broad range on baseline expression within the population, which
makes them notoriously bad predictors of future events. Further-
more, in certain cases, a profile of multiple markers may shed
more light on the cancer status than a single marker.
The limitation of sensitivity can be resolved by reducing the
dimensions to the nanoscale. Using the dip-pen nanolithography
approach, Mirkin’s group printed a nanoscale oligonucleotide chip
on both metallic and insulating substrates, which exhibited the
sequence-specific binding properties of the DNA (Demers et al,
2002). This ‘bottom-up’ approach can enable the detection of
markers at very low concentrations, especially when integrated
with another emerging technology, the nanocantilevers.
The nanocantilevers-based sensors operate on the concept that
biomolecular binding events will deflect the nanocantilevers
resulting in a change in their resonating frequencies (Fritz et al,
2000) (Figure 1). The nanoscale dimensions offer the possibility
of designing structures with multiple such components, each with
distinct detection capabilities, which can allow the simultaneous
profiling of a range of predictors for a given cancer. Furthermore,
the reduction in the dimension also holds the promise of
increasing the sensitivity to a scale where it is possible to detect
subtle changes in the profile. For example, using a microscale
cantilever, Hansen et al (2001) reported that it was possible to
discriminate DNA single-nucleotide mismatches. In a separate
study, Wu et al (2001) demonstrated the feasibility of the approach
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www.bjcancer.comto quantify PSA at a clinically relevant concentration. Although
both these studies were done using a microscale cantilever, it is not
difficult to envisage a future where nanowires and nanotubes will
function as the sensors (Zheng et al, 2005), offering the possibility
of large-scale monitoring of the proteome or the transcriptome
for subtle changes in the profile and relate it to the early stages of
cancer progression.
Another emerging area is the use of nanoparticles for
diagnostics (Cuenca et al, 2006). For example, Mirkin and co-
workers developed a system that relies on nanoparticle probes
encoded with DNA that are unique to the protein target of interest,
and antibodies that can sandwich the target captured by the
probes. Magnetic separation of the target–probe complex followed
by dehybridisation of the oligonucleotides on the nanoparticle
probe surface allows the determination of the presence of the
target protein. Using this approach, they could attain substantial
amplification as each nanoparticle probe carried with it a large
number of oligonucleotides per protein binding event. Adding a
polymerase chain reaction on the oligonucleotide bar codes could
boost the sensitivity of detecting PSA to 3aM which is six orders of
magnitude more sensitive than the clinically accepted conventional
assays (Rosi and Mirkin, 2005). In other studies, gold nanoshell-
based immunoassays that change colour following interactions
with the ligand and quantum dots labelled with targeting
antibodies have been used to detect specific tumour markers.
These offer significant advantages of stability and ‘tunability’ over
traditional staining techniques; in particular, they do not
photobleach and can be designed to emit different colours based
on their sizes.
NANOTECHNOLOGY AND TUMOUR IMAGING
Although the use of nanotechnology has generated excitement in
the area of tumour biology, especially enabling the simultaneous
monitoring of multiple cellular markers based on the tunability of
the nanostructures, another application that is achieving major
milestones towards clinical applicability is the use of nanoparticles
to image tumours in vivo.
Iron oxide nanocrystals (Figure 2) with superparamagnetic
properties have been used as contrast agents in magnetic
resonance imaging (MRI) as they cause changes in the spin–spin
relaxation times of the neighbouring water molecules (Moghimi
et al, 2005). In an interesting study, highly lymphotropic super-
paramagnetic nanoparticles, which gain access to lymph nodes by
means of interstitial–lymphatic fluid transport, were used in
conjunction with high-resolution MRI to reveal small and
otherwise undetectable lymph-node metastases in patients with
prostate cancer (Harisinghani et al, 2003).
Quantum dots, which are generally defined as particles with
physical dimensions smaller than the exciton Bohr radius (Chan
et al, 2002), are emerging as powerful optical contrast agents, both
for monitoring cellular events and for imaging tumours in vivo.
Quantum dots (Qdots) offer unique size- and composition-tunable
fluorescence emission from visible to infra-red wavelengths, large
absorption coefficients across a wide spectral range and greater
phostability and signal intensity. Initial concerns regarding
nonselective uptake of Qdots into the reticuloendothelial system
and solubility were overcome using pegylation chemistry
(Akerman et al, 2002), which results in a hydrophilic surface.
Furthermore, coating with a targeting peptide resulted in the
selective delivery to the target organs such as tumour vasculature
or the lungs (Akerman et al, 2002).
Quantum dots have now been used track signalling pathways,
such as the erbB/HER receptor-mediated signalling (Lidke et al,
2004), cell–cell interaction, such as in breast tumour (Alivisatos
et al, 2005), and for spectrally distinguishing multiple species
within the tumour milieu in vivo (Stroh et al, 2005). Furthermore,
labelling the tumour cells with Qdots also enabled the tracking of
metastatic tumour cell extravasation (Voura et al, 2004). The last
study also established the safety profile of Qdots in vivo, although
extensive safety and pharmacokinetics studies need to be carried
out before use in humans given the fact that Qdots are composed
of heavy metals (such as Cd), which can induce liver and kidney
damage. However, one should also consider that before biological
use the metals are sequestered inside an organic shell, and are
administered at doses much below the known toxic levels of the
metals.
The advantages of using Qdots over traditional radiocontrast
dyes lies in the avoidance of harmful radiations that are
traditionally used. The Qdots that emit at longer wavelengths are
especially suitable for in vivo imaging as there is low tissue
scattering and absorption in this range. However, the goal is to
preserve the optical properties of these Qdots following surface
modifications to make them biocompatible (Jiang et al, 2004).
Emergence of newer technologies that enable biocompatible Qdots
with narrow emission spectral range and enhanced photostability –
and their integration with improved pattern recognition and image
analysis techniques – will revolutionise the tumour imaging field.
NANOTECHNOLOGY AND TUMOUR DRUG DELIVERY
One of the earliest applications of nanotechnology in medicine was
the use of liposomes in the nanoscale range to deliver chemo-
therapy payloads to the tumour (Moghimi et al, 2005). Liposomal
formulations of doxorubicin are now approved for use in Kaposi
sarcoma, breast cancer and refractory ovarian cancer. An
advantage that the liposomes provided is the delivery in an
aqueous phase, which avoided the use of solubilising agents such
as Cremophor that are associated with hypersensitivity reactions.
A major milestone in drug delivery systems engineering was the
development of technologies that can mask the nanodelivery
carriers from the immune system. Significant modifications have
been introduced in the composition of the lipid bilayers that have
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Figure 1 (A) s.e.m. of a cantilever. Reused with permission from A
Gupta, D Akin and R Bashir, J of Vaccum Science and Technology B, 22,
2785 (2004). Copyright 2004, AVS The Science and Technology Society.
(B) Schematic showing the functionalisation of the cantilever such that it
can bind to a cancer marker. The cantilever can be set to a defined
frequency that changes following the binding of a marker. Reducing the
cantilever to the nanoscale size can enable highly sensitive detection of
cancer markers. Reused with permission from A Gupta, D Akin and R
Bashir. Applied physics letters, 84, 1996 (2004), copyright 2004, American
Institute of Physics.
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specific homing. For example, the introduction of synthetic lipid
derivatives of polyethylene, where the hydrophilicity of the PEG
chains confers ‘stealth’ capability to the liposomes (Allen et al,
1991). These liposomes remain in the circulation for prolonged
periods of time and accumulate passively in the tumours via an
enhanced permeation and retention (EPR) effect (Yuan et al,
1994). The EPR effect arises from the unique morphology of the
tumour vasculature, which is highly leaky with pore sizes as large
as 600nm that allows the nanoscale liposomes to easily extravasate
out into the tumour. Furthermore, the limited lymphatic drainage
prevents the clearance from the tumours. Passive targeting
through the EPR effect results in delivery of 3–10 times more
drug to solid tumours as compared to free drug. Indeed, the
clinical liposomal formulations of doxorubicin were shown to
deliver between 5 and 11 times more doxorubicin to Kaposi’s
sarcoma lesions than to normal skin, leading to an overall tumour
response rate as high as 80%. However, selective delivery can be
further improved upon by integrating targeting technologies to the
delivery platform. One of the attractive targets for ‘homing’ has
been the dividing endothelium, which is a hallmark of the tumour
vessels. For example, a nanoparticle carrying a plasmid DNA
encoding a dominant-negative mutant form of RAF kinase was
reported to exert antiangiogenesis effects when targeted against
avb3 integrins (Hood et al, 2002). There are still bottlenecks in the
existing ‘homing’ technologies, such as in the case of targeting
TNP470-immunoliposomes using a single-chain variable fragment
against human endoglin on angiogenic endothelial cells resulted in
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Figure 2 Electron micrographs of different types of nanoparticles. (A) Fe nanoparticles coated with poly(N-vinyl-2-pyrrolidone), which stabilises the
nanoparticles. (B) TEM image of Au nanoparticles, (B6nm), which are being harnessed for sensing protein markers. The aggregation of these nanoparticles
is visualised from a change in absorbance; (C) TEM image for Fe3O4 nanoparticles (size B5nm), which are being developed as radiocontrast agents. (D)
TEM image for CdSe quantum dots (size B4nm). The size-dependent optical tunability of quantum dots make them ideal candidates for imaging. Courtesy
of Dr Zhi-Hui Ban, MIT. Inset shows electron micrographs of a nanocore and a nanocell. (a) Scanning electron micrograph of a nanocore synthesised from
doxorubicin-conjugated PLGA polymer. (b) Transmission electron micrograph of a cross-section of a nanocell. The dark centre is the nanocore entrapped
inside the lipid layer. The hybrid two-chambered nanoparticle displays a spatiotemporal release kinetics, rapidly releasing an antiangiogenesis agent from the
outer layer follwed by a delayed release of a chemotherapeutic agent. The release of the antiangiogenesis agent causes a vascular collapse entrapping the
chemotherapy-loaded nanocore within the tumour. As the tumour becomes hypoxic, the nanocore degrades, focally releasing the chemotherapy agent.
(Sengupta et al, 2005).
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targeting mechanism. This emphasises the need for novel targeting
strategies, such as using aptamer (Farokhzad et al, 2006).
Another emerging approach for specifically targeting the
tumour cells without collateral damage is the polymer-directed
enzyme prodrug therapy, which uses a combination of a polymeric
prodrug and polymer-enzyme conjugate to generate a cytotoxic
drug rapidly and selectively within the tumours. Several polymer-
cyotoxic drug conjugates are already in early clinical trials,
including N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-
doxorubicin, paclitaxel, HPMA-platinate and PEG-campothecin.
Recently, a conjugate of TNP470 and HPMA was also shown to be
an effective antiangiogenesis therapy (Satchi-Fainaro et al, 2004),
homing into tumours through the EPR effect with a concomitant
reduction in toxicity. The advantages of the HPMA copolymer
were also the presence of multivalent side chains that permits a
higher loading of drugs on the polymer and the reduced
immunogenic profile that allows repeated dosing.
Approaches based on the conjugation of chemotherapeutic
agents with nanoparticle-forming biodegradable polymers have
long been developed (Sengupta et al, 2005), avoiding the ‘burst
release’ associated with nanoparticles. However, the limitation of
using polymers such as PLGA remains in the limited number of
valent sites to which a chemotherapeutic agent could be coupled.
An emerging approach to overcome this limitation is the use of
dendrimers, which are synthetic, highly branched, symmetrical
macromolecules. Altering the terminal functionalities of the
dendrimers (such as PAMAMs and PPIs) enables targeted drug
delivery, whereas the interior cavities can be used for loading both
hydrophobic and hydrophilic drugs. However, further character-
isation of the dendrimers is needed to determine their safety
profile before they can reach the clinics.
FUTURE DIRECTIONS
Although most of the technologies have focused on the delivery of
single chemotherapeutic agents to the tumours, it is increasingly
becoming clear that an integrative approach may work better than
a reductionist approach. Nanotechnology platforms can provide
the unique niche within this space by enabling multimodal delivery
with a single application. For example, in a recent study, we
demonstrated that the spatiotemporal release of an antiangio-
genesis agent and a chemotherapeutic agent from a hybrid
nanoparticle, a ‘nanocell’ (Figure 2) could exert a better
therapeutic outcome as compared with existing delivery ap-
proaches (Sengupta et al, 2005). A nanocell comprises of a
pegylated phospholipid outer layer entrapping a nanocore. An
antiangiogenic agent is partitioned into the lipid layer, whereas a
chemotherapeutic agent is conjugated to a biodegradable polymer
to generate the nanocores. The nanocell homes into the tumour
vasculature through the EPR effect and releases the antiangiogenic
agent, resulting in the collapse of the tumour vasculature. The
chemotherapy agent is then slowly released from the entrapped
nanocores, inducing apoptosis and overcoming the potential for
hypoxia-induced ‘reactive resistance’.
Another emerging direction in the application of nanotechno-
logy in cancer is the use of self-assembly techniques, such as to
design monodisperse delivery vehicles like polymerosomes (Xu
et al, 2005) or to develop sensors. Nanotechnology is also enabling
highly efficent radiotherapy, such as the injection of single doses of
an atomic nanogenerator at kilobecquerel (nanocurie) levels into
mice bearing solid prostate carcinoma or disseminated human
lymphoma induced tumour regression and prolonged survival,
without toxicity, in a substantial fraction of animals (McDevitt
et al, 2001). In another study, metal nanoshells with tunable optical
resonance were shown to induce irreversible thermal damage to
tumour cells when exposed to near infrared light (Hirsch et al,
2003).
Nanotechnology clearly holds immense potential for targeting
cancer. These approaches will encompass the desired goals of early
detection, tumour regression with limited collateral damages, and
efficient monitoring of response to chemotherapy. The exciting
milestones made in these areas need to be paralleled with safety
evaluations of the platforms before they are translated to the
clinics. Nevertheless, we believe that the next few years are likely to
see an increasing number of nanotechnology-based therapeutics
and diagnostics reaching the clinic.
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